ISSN: 2455 - 927X

EIJO: Journal of Humanities, Social Affair, Management and Innovative Research (EIJO– JHSAMIR)

Einstein International Journal Organization (EIJO)

Available Online at: www.eijo.in

Volume – 11, Issue – 1, January - February - 2026, Page No. : 10 – 20

Quality-by-Design Approaches in Insulin-Loaded Nanoparticles for Oral Drug Delivery: Challenges and Future Perspectives

[1]Mansi Sharma, [2]Kajal Gupta

[1-2]Jaipur School of Pharmacy, Maharaj Vinayak Global University, Jaipur, Rajasthan

Abstract

Oral insulin delivery remains a long-standing goal in diabetes therapy because it offers a non-invasive alternative to injections and better mimics physiological insulin distribution through portal circulation. However, insulin is highly susceptible to gastrointestinal enzymatic degradation, variable pH conditions, mucus barriers, and limited epithelial permeability, resulting in extremely low oral bioavailability. Nanoparticle-based delivery systems have emerged as promising carriers capable of protecting insulin, enhancing intestinal absorption, and enabling controlled release. Incorporation of Quality-by-Design (QbD) principles in nanoparticle development allows systematic optimization of formulation variables such as particle size, surface charge, encapsulation efficiency, and stability to ensure consistent product quality and performance. Despite encouraging preclinical results, challenges including scalability, regulatory approval, reproducibility, long-term safety, and clinical translation persist. Future research integrating advanced materials, predictive modeling, regulatory harmonization, and patient-centric design is expected to accelerate the successful development of oral insulin nanomedicines.

Keywords: Oral Insulin Delivery, Nanoparticles, Quality-By-Design, Nanomedicine, Drug Delivery Systems, Diabetes Therapy, Bioavailability Enhancement, Controlled Release.

1. Introduction

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin resistance, or both. It is one of the fastest-growing global health concerns, affecting millions of individuals worldwide and placing a substantial burden on healthcare systems. Effective glycemic control is essential to prevent acute complications such as hypoglycemia and ketoacidosis, as well as long-term complications including neuropathy, nephropathy, retinopathy, and cardiovascular diseases. For many patients, especially those with type 1 diabetes and advanced type 2 diabetes, insulin therapy remains the cornerstone of treatment. Despite its proven therapeutic effectiveness, conventional insulin administration is predominantly achieved through subcutaneous injections, which often present practical and physiological challenges.

Repeated injections can cause pain, needle anxiety, local tissue irritation, and poor patient compliance, particularly in elderly individuals, children, and those requiring lifelong therapy. Furthermore, injected insulin enters systemic circulation directly rather than first passing through the liver, which differs from the natural physiological pathway of endogenous insulin secretion. Normally, insulin released by pancreatic β-cells enters the portal vein and reaches the liver before systemic distribution, where it regulates hepatic glucose production efficiently. Subcutaneous insulin administration bypasses this hepatic first-pass effect, sometimes resulting in peripheral hyperinsulinemia and suboptimal

metabolic control. Consequently, alternative insulin delivery routes that mimic physiological insulin distribution have been a major focus of pharmaceutical research.

Oral insulin delivery has emerged as a promising strategy because it is non-invasive, convenient, and potentially capable of restoring the physiological pathway of insulin absorption through the gastrointestinal tract into portal circulation. Such an approach could significantly improve patient adherence, enhance quality of life, and provide more natural glycemic regulation. However, the oral route presents formidable biological barriers that severely limit insulin bioavailability. Insulin is a peptide hormone susceptible to enzymatic degradation in the harsh gastrointestinal environment. Proteolytic enzymes such as pepsin in the stomach and trypsin and chymotrypsin in the intestine rapidly degrade insulin into inactive fragments before it can be absorbed.

In addition to enzymatic degradation, the acidic gastric pH can destabilize insulin's three-dimensional structure, leading to denaturation and reduced activity. Even if insulin survives chemical and enzymatic degradation, it must still traverse the mucus layer covering the intestinal epithelium. This mucus barrier acts as a protective gel that traps foreign particles, limiting drug diffusion toward epithelial cells. The epithelial lining itself forms another critical barrier due to tight junctions between cells, which restrict paracellular transport of macromolecules such as insulin. Transcellular transport is also limited because insulin is hydrophilic and relatively large in molecular size, making passive diffusion across lipid cell membranes inefficient.

Furthermore, variability in gastrointestinal transit time, food interactions, and intestinal motility can influence absorption patterns, leading to inconsistent pharmacokinetics. These factors collectively result in extremely low oral insulin bioavailability, often reported to be less than 1% in conventional formulations. Such limitations have historically hindered the clinical translation of oral insulin products despite decades of research.

To overcome these challenges, advanced drug delivery technologies have been explored, among which nanoparticle-based systems have gained significant attention. Nanoparticles are submicron-sized carriers engineered from polymers, lipids, proteins, or inorganic materials capable of encapsulating therapeutic agents. Their small size and tunable physicochemical properties enable protection of insulin from enzymatic degradation, enhancement of intestinal permeation, and controlled drug release. By modifying nanoparticle surface characteristics, such as charge, hydrophilicity, and ligand attachment, it is possible to improve mucoadhesion, facilitate epithelial uptake, and prolong gastrointestinal residence time.

Polymeric nanoparticles, lipid-based nanocarriers, nanoemulsions, liposomes, and hydrogel-based nanosystems have all demonstrated potential in experimental studies for improving oral insulin delivery. These carriers can shield insulin from gastric acidity and proteolytic enzymes while providing targeted delivery to absorption sites in the intestine. Additionally, some nanoparticle systems are designed to respond to environmental triggers such as pH or enzymatic activity, enabling site-specific release of insulin where absorption is most favorable.

Despite encouraging progress, the successful development of oral insulin nanoparticles requires careful formulation optimization, process control, and quality assurance. Variability in particle size, encapsulation efficiency, surface properties, and release kinetics can significantly influence therapeutic performance. Consequently, systematic pharmaceutical development approaches such as Quality-by-Design (QbD) have become increasingly important in

© 2026 EIJO, All Rights Reserved

nanoparticle formulation research. QbD emphasizes understanding the relationship between formulation variables, manufacturing processes, and product quality attributes to ensure consistent safety, efficacy, and reproducibility.

The integration of nanotechnology with QbD principles offers a structured pathway toward the rational design of oral insulin delivery systems. It enables identification of critical formulation parameters, optimization through statistical experimental designs, and development of scalable manufacturing processes suitable for clinical and commercial applications. Nevertheless, challenges related to regulatory approval, large-scale production, long-term safety evaluation, and clinical validation remain substantial.

Overall, oral insulin nanoparticle systems represent a promising frontier in diabetes management. Continued advances in materials science, pharmaceutical engineering, and regulatory science are expected to facilitate the translation of these innovative systems from laboratory research to practical therapeutic solutions. The development of safe, effective, and patient-friendly oral insulin formulations could significantly transform diabetes treatment by improving compliance, enhancing metabolic control, and reducing the burden associated with lifelong injectable therapy.

2. Oral Insulin Delivery Barriers

Oral delivery of insulin represents an attractive alternative to injectable therapy because it offers improved patient convenience, better compliance, and the possibility of mimicking physiological insulin transport through the portal circulation. However, successful oral insulin administration remains extremely challenging due to several biological, physiological, and pharmacokinetic barriers. These obstacles significantly reduce insulin stability, absorption, and overall bioavailability, making formulation development complex. Understanding these barriers is essential for designing effective nanoparticle-based oral insulin delivery systems.



2.1 Gastrointestinal Degradation

One of the most significant obstacles to oral insulin delivery is the harsh gastrointestinal (GI) environment. Insulin is a peptide hormone composed of amino acid chains held together by disulfide bonds, making it highly susceptible to enzymatic degradation. After oral administration, insulin first encounters the acidic gastric environment, where the low pH can cause denaturation of its tertiary structure. This structural alteration can lead to loss of biological activity even before enzymatic degradation begins.

© 2026 EIJO, All Rights Reserved

Proteolytic enzymes present throughout the gastrointestinal tract further accelerate insulin breakdown. In the stomach, pepsin initiates protein digestion by cleaving peptide bonds. As insulin passes into the small intestine, pancreatic enzymes such as trypsin, chymotrypsin, elastase, and carboxypeptidases continue the degradation process. These enzymes rapidly hydrolyze insulin into smaller, inactive peptide fragments that cannot exert therapeutic effects.

Additionally, the presence of bile salts and digestive surfactants can destabilize insulin molecules and affect their structural integrity. Food components, pH fluctuations, and gastrointestinal motility further complicate stability. Consequently, only a very small fraction of orally administered insulin remains intact long enough to be potentially absorbed.

Various formulation strategies, including enzyme inhibitors, enteric coatings, and nanoparticle encapsulation, have been investigated to protect insulin from enzymatic degradation. Encapsulation within nanoparticles can physically shield insulin from proteolytic enzymes while maintaining its structural stability until it reaches the absorption site in the intestine. Nevertheless, achieving sufficient protection without compromising drug release remains a major formulation challenge.

2.2 Physiological Barriers

Beyond enzymatic degradation, several physiological barriers in the gastrointestinal tract hinder insulin absorption. One of the primary obstacles is the mucus layer covering the intestinal epithelium. This mucus acts as a protective barrier against pathogens and foreign particles by trapping macromolecules and limiting their diffusion toward epithelial cells. Insulin, being hydrophilic and relatively large, faces significant difficulty penetrating this viscous mucus network.

The epithelial cell lining of the intestine forms another critical barrier. Tight junctions between epithelial cells restrict paracellular transport, preventing large molecules like insulin from passing between cells. Transcellular transport, which involves passage through epithelial cells, is also inefficient for insulin due to its high molecular weight and hydrophilic nature. Passive diffusion across lipid membranes is minimal, and active transport mechanisms for insulin are limited.

Microvilli structures on intestinal epithelial cells, although designed to increase absorptive surface area, also create a complex physical landscape that may hinder uniform drug distribution. Additionally, efflux transporters present in intestinal cells can actively pump certain molecules back into the intestinal lumen, further reducing absorption.

First-pass hepatic metabolism adds another layer of complexity. Even if a fraction of insulin is absorbed into portal circulation, hepatic enzymes may metabolize a significant portion before it reaches systemic circulation. While this hepatic first-pass effect is physiologically desirable for endogenous insulin, excessive metabolism of orally administered insulin may reduce therapeutic efficacy.

To overcome physiological barriers, modern delivery systems aim to enhance mucoadhesion, increase epithelial permeability, or utilize receptor-mediated transport pathways. Nanoparticles can be engineered with surface modifications such as targeting ligands, mucoadhesive polymers, or permeation enhancers to facilitate better absorption. However, balancing enhanced permeability with safety remains an ongoing concern.

2.3 Pharmacokinetic Limitations

Pharmacokinetic variability is another major challenge in oral insulin delivery. Compared with injectable insulin, orally administered insulin often shows delayed onset of action due to slower absorption through the gastrointestinal tract.

© 2026 EIJO, All Rights Reserved

Gastric emptying time, intestinal transit rate, food intake, and physiological conditions can all influence absorption patterns, leading to unpredictable plasma insulin levels.

Low and inconsistent bioavailability is a key pharmacokinetic limitation. In many experimental formulations, oral insulin bioavailability remains below 1–2%, which is insufficient for consistent glycemic control. Achieving therapeutic plasma concentrations often requires higher doses, increasing the risk of formulation instability and potential side effects.

Inter-individual variability also complicates pharmacokinetic outcomes. Differences in gastrointestinal pH, enzyme activity, microbiota composition, mucosal thickness, and disease state can significantly affect insulin absorption. Such variability makes it difficult to design universally effective oral formulations.

Furthermore, maintaining sustained and controlled insulin release is essential to avoid hypoglycemic episodes. Rapid or uncontrolled insulin release may cause sudden drops in blood glucose levels, whereas insufficient release may lead to hyperglycemia. Achieving an optimal balance between protection, absorption, and controlled release is therefore a critical formulation goal.

Nanoparticle-based systems aim to address pharmacokinetic limitations by enhancing stability, prolonging gastrointestinal residence time, and enabling controlled drug release. Some advanced nanoparticles are designed to respond to environmental triggers such as pH changes, enzymatic activity, or glucose levels, offering potential for more precise insulin delivery. Despite these promising approaches, consistent pharmacokinetic performance in clinical settings remains a challenge.

3. Insulin-Loaded Nanoparticles for Oral Delivery

The development of insulin-loaded nanoparticle systems has emerged as a promising strategy to overcome the major barriers associated with oral insulin delivery. Insulin, being a peptide hormone, is highly susceptible to degradation in the gastrointestinal tract and exhibits poor permeability across the intestinal epithelium. Nanoparticles, typically ranging from 10 to 1000 nm in size, serve as protective carriers capable of encapsulating insulin, shielding it from harsh gastric conditions, and facilitating its absorption through the intestinal mucosa. These systems not only enhance insulin stability but also enable targeted delivery and controlled release, improving therapeutic efficiency and patient compliance.

One of the primary advantages of nanoparticle-based oral insulin delivery is protection against enzymatic degradation. Encapsulation within nanoparticles creates a physical barrier between insulin molecules and gastrointestinal proteolytic enzymes such as pepsin, trypsin, and chymotrypsin. Additionally, certain nanoparticle formulations incorporate enzyme inhibitors or pH-responsive coatings that further protect insulin until it reaches the intestine, where absorption is more favorable. This protective effect significantly increases the fraction of intact insulin available for absorption.

Various types of nanoparticle systems have been explored for oral insulin delivery. Polymeric nanoparticles, commonly prepared from biodegradable polymers such as chitosan, poly(lactic-co-glycolic acid) (PLGA), and alginate, have demonstrated excellent biocompatibility and mucoadhesive properties. These polymers can enhance residence time in the gastrointestinal tract and promote paracellular transport by transiently opening tight junctions in the intestinal epithelium. Lipid-based nanoparticles, including solid lipid nanoparticles and nanostructured lipid carriers, offer advantages such as improved biocompatibility, enhanced membrane permeability, and efficient drug loading capacity. Lipid nanoparticles can facilitate transcellular absorption by interacting with cell membranes and promoting lymphatic uptake.

© 2026 EIJO, All Rights Reserved

Hydrogel-based nanoparticles represent another innovative approach, particularly for pH-responsive drug delivery. These systems swell or shrink in response to environmental pH changes, allowing insulin release specifically in the intestine while minimizing exposure to acidic gastric conditions. Inorganic nanocarriers, such as silica nanoparticles and gold nanoparticles, have also been investigated due to their structural stability and capacity for surface functionalization, although concerns about long-term safety and biodegradability remain under evaluation.

Encapsulation of insulin within nanoparticles has been shown to increase relative oral bioavailability several-fold compared with conventional formulations. Nanoparticles enhance drug absorption through multiple mechanisms, including improved mucoadhesion, protection from enzymatic degradation, facilitated epithelial uptake, and sustained drug release. Surface modification of nanoparticles with targeting ligands or permeation enhancers can further improve intestinal transport by promoting receptor-mediated endocytosis or transiently increasing epithelial permeability.

Controlled release is another important benefit of nanoparticle systems. By adjusting polymer composition, particle size, and surface characteristics, researchers can design nanoparticles that release insulin gradually over time, helping maintain stable plasma glucose levels and reducing the risk of hypoglycemic episodes. Such sustained release profiles are particularly valuable in chronic diabetes management, where consistent insulin availability is essential.

Despite promising experimental results, several challenges remain before widespread clinical application can be achieved. Issues such as large-scale manufacturing, long-term stability, reproducibility, and regulatory approval must be addressed. Nevertheless, continued advances in nanotechnology, materials science, and pharmaceutical formulation are expected to further improve the performance of insulin-loaded nanoparticles.

4. Quality-by-Design (QbD) in Nanoparticle Formulation

Quality-by-Design (QbD) is a modern pharmaceutical development approach that emphasizes systematic product design, scientific understanding of processes, and risk-based quality assurance rather than relying solely on end-product testing. In the context of insulin-loaded nanoparticles for oral delivery, QbD provides a structured framework to ensure consistent product quality, safety, and therapeutic efficacy. Since nanoparticle formulations are complex systems influenced by multiple formulation variables and manufacturing conditions, the QbD approach helps identify critical parameters early in development and optimize them to achieve desired performance characteristics. This systematic strategy enhances reproducibility, scalability, regulatory acceptance, and overall product reliability.

Nanoparticle-based insulin delivery systems must overcome numerous biological and physicochemical challenges such as enzymatic degradation, variable gastrointestinal conditions, and limited epithelial permeability. The QbD framework supports rational formulation design by linking product characteristics with clinical performance. It involves defining clear objectives, identifying critical attributes, controlling process parameters, and applying statistical tools for optimization. These steps collectively ensure robust formulation development and minimize variability during manufacturing.

- **Identification of Quality Target Product Profile (QTPP)**

The Quality Target Product Profile (QTPP) represents the prospective summary of quality characteristics required to ensure desired safety and efficacy of the pharmaceutical product. For insulin-loaded nanoparticles intended for oral

© 2026 EIJO, All Rights Reserved

delivery, the QTPP includes parameters such as optimal particle size, desired drug release profile, high encapsulation efficiency, adequate stability under gastrointestinal conditions, and improved oral bioavailability.

A key objective of the QTPP in oral insulin formulations is to mimic physiological insulin release while protecting the drug from degradation in the stomach. The formulation should provide controlled release in the intestine, ensuring efficient absorption and sustained therapeutic action. Stability during storage, resistance to moisture and temperature variations, and compatibility with excipients are also critical considerations. Additionally, patient acceptability, dosage form convenience, and safety requirements are integral aspects of the QTPP.

Defining the QTPP at the initial stage helps guide formulation scientists in selecting appropriate materials, nanoparticle preparation methods, and process conditions. It establishes a target framework against which formulation performance can be evaluated throughout development.

- **Critical Quality Attributes (CQAs)**

Critical Quality Attributes (CQAs) are the physical, chemical, biological, or microbiological properties that must be controlled within predefined limits to ensure product quality. For insulin-loaded nanoparticles, several CQAs significantly influence formulation performance.

Particle size is one of the most important CQAs because it affects drug absorption, cellular uptake, distribution, and stability. Smaller nanoparticles generally exhibit enhanced mucosal penetration and improved intestinal absorption. Surface charge, typically measured as zeta potential, influences nanoparticle stability, mucoadhesion, and interaction with biological membranes. A suitable zeta potential helps prevent aggregation and enhances formulation stability.

Drug loading capacity and encapsulation efficiency are crucial for achieving therapeutic dosing while minimizing formulation bulk. High encapsulation efficiency ensures maximum protection of insulin from enzymatic degradation. Release kinetics is another important CQA, as controlled and sustained release helps maintain stable plasma insulin levels and reduces fluctuations in blood glucose concentration.

Other CQAs may include morphology, crystallinity, viscosity, pH stability, and in vitro drug release behavior. Comprehensive characterization of these attributes ensures consistent product quality and reliable therapeutic performance.

- **Critical Process Parameters (CPPs)**

Critical Process Parameters (CPPs) refer to manufacturing variables that significantly influence CQAs and overall product quality. In nanoparticle formulation, numerous process parameters can affect particle characteristics and stability.

Polymer concentration is a major CPP, as it determines nanoparticle size, drug encapsulation efficiency, and release profile. The choice of solvent system also plays a crucial role in nanoparticle formation, affecting solubility, particle morphology, and residual solvent content. Mixing speed and homogenization conditions influence particle size distribution, uniformity, and dispersion stability.

Temperature control during preparation is essential because excessive heat may degrade insulin or alter polymer properties. Drying methods such as freeze-drying or spray-drying can affect nanoparticle stability, aggregation tendency, and long-term storage characteristics. Proper optimization of drying conditions helps preserve insulin activity and maintain nanoparticle integrity.

© 2026 EIJO, All Rights Reserved

Monitoring and controlling CPPs ensure reproducible manufacturing processes and consistent product performance. Establishing acceptable operating ranges for each parameter helps maintain formulation robustness during scale-up and commercial production.

- **Risk Assessment Tools**

Risk assessment is a core component of the QbD framework. It involves identifying potential factors that may impact product quality and evaluating their likelihood and severity. Tools such as Design of Experiments (DoE), statistical modeling, failure mode and effects analysis (FMEA), and multivariate analysis are commonly used in nanoparticle formulation development.

Design of Experiments enables systematic evaluation of multiple formulation variables simultaneously. By studying interactions among variables such as polymer concentration, surfactant level, and mixing conditions, researchers can identify optimal formulation settings with minimal experimental trials. Statistical modeling further supports prediction of formulation behavior under different conditions.

Risk assessment also aids in identifying critical control points in the manufacturing process. This proactive approach helps prevent formulation failures, ensures product consistency, and facilitates regulatory compliance. Optimization strategies derived from risk assessment improve efficiency, reduce development time, and enhance overall product quality.

- **Significance of QbD in Oral Insulin Nanoparticles**

Applying QbD principles to insulin-loaded nanoparticle systems offers several advantages. It promotes a scientific understanding of formulation variables, enhances process control, supports scale-up feasibility, and improves regulatory acceptance. By systematically linking formulation attributes with therapeutic outcomes, QbD facilitates development of reliable and effective oral insulin delivery systems.

Furthermore, QbD encourages continuous improvement throughout the product lifecycle. Post-approval changes can be managed effectively through established design space knowledge, ensuring consistent product quality. This approach ultimately contributes to safer, more effective, and patient-friendly insulin therapies.

5.1 Biological and Clinical Challenges

One of the most critical challenges in oral insulin nanoparticle development is extremely low bioavailability. Even with advanced nanoparticle carriers, insulin remains vulnerable to degradation in the gastrointestinal tract. Proteolytic enzymes, acidic gastric conditions, and mucosal barriers significantly reduce the fraction of intact insulin available for absorption. Although nanoparticle encapsulation provides some protection, achieving therapeutically relevant bioavailability remains difficult.

Another major challenge is the translation of encouraging preclinical findings into successful human clinical outcomes. Many nanoparticle formulations demonstrate improved insulin absorption and glycemic control in animal models, but these results often fail to replicate in human studies. Differences in gastrointestinal physiology, enzyme activity, immune responses, and metabolic processes between animals and humans contribute to variability in clinical outcomes. Additionally, inter-individual differences in diet, gut microbiota, and disease progression can further complicate clinical performance. These factors highlight the need for more predictive preclinical models and well-designed clinical trials to ensure successful translation.

© 2026 EIJO, All Rights Reserved

5.2 Manufacturing and Scalability Issues

Manufacturing complexity is another significant barrier in the development of QbD-based insulin nanoparticle systems. Nanoparticle fabrication involves multiple formulation variables such as polymer concentration, solvent selection, mixing conditions, and temperature control. Small variations in these parameters can affect particle size, encapsulation efficiency, stability, and release characteristics. Maintaining consistent product quality during scale-up from laboratory to industrial production remains a challenging task.

Stability during storage is also a major concern. Nanoparticles may undergo aggregation, sedimentation, or chemical degradation over time, which can compromise insulin activity and therapeutic effectiveness. Drying processes such as freeze-drying or spray-drying, often used to improve shelf-life, may cause structural changes, aggregation, or loss of biological activity. Reconstitution of dried nanoparticles may not always restore their original physicochemical properties, affecting performance. QbD approaches help identify critical process parameters, but achieving long-term stability and reproducibility at commercial scale still requires further optimization.

5.3 Safety and Regulatory Concerns

Safety considerations are particularly important for nanoparticle-based drug delivery systems. Some nanomaterials, especially non-biodegradable inorganic carriers, may accumulate in tissues following repeated administration, raising concerns about long-term toxicity. Potential immunogenic responses, inflammation, and unexpected biological interactions must be carefully evaluated through comprehensive preclinical and clinical studies.

Regulatory approval presents additional challenges. Nanoparticle formulations often exhibit complex physicochemical properties that require advanced analytical characterization. Regulatory agencies demand rigorous evaluation of particle size distribution, surface properties, drug release kinetics, stability, and biocompatibility. The lack of universally harmonized regulatory guidelines for nanomedicines can further complicate approval processes. Implementing QbD principles can facilitate regulatory acceptance by providing a systematic understanding of product quality attributes and manufacturing processes, but extensive documentation and validation are still required.

Table 1: Future Perspectives in QbD-Based Oral Insulin Nanoparticles

Future Direction	Description / Significance
Biodegradable and Stimuli-Responsive Nanoparticles	Development of biodegradable carriers that safely degrade in the body, along with stimuli-responsive systems (pH, enzyme, or glucose-responsive) to enable targeted and controlled insulin release in the gastrointestinal tract.
Integration of Artificial Intelligence with QbD	Use of artificial intelligence, machine learning, and predictive modeling to optimize formulation parameters, reduce experimental workload, improve risk assessment, and enhance product consistency within the QbD framework.
Improved In Vitro–In Vivo Correlation Models	Establishment of reliable laboratory models that better predict human clinical performance, helping bridge the gap between preclinical studies and clinical success of oral insulin nanoparticle systems.
Personalized Insulin Delivery	Development of patient-specific formulations considering physiological variability,

© 2026 EIJO, All Rights Reserved

Systems	disease severity, metabolic rate, and lifestyle factors to improve therapeutic outcomes and minimize side effects.
Standardization of Regulatory Guidelines	Creation of harmonized global regulatory frameworks for nanomedicines to ensure consistent quality evaluation, safety assessment, and smoother approval processes for oral insulin nanoparticle formulations.
Cost-Effective Large-Scale Manufacturing	Advancement of scalable, economical production technologies that maintain nanoparticle stability, reproducibility, and quality while reducing overall manufacturing costs.

6. Conclusion

Quality-by-Design (QbD) approaches offer a systematic and scientific framework for the development of insulin-loaded nanoparticles intended for oral drug delivery. By emphasizing product understanding, risk assessment, and process optimization, QbD helps ensure consistent formulation quality, safety, and therapeutic efficacy. Nanoparticle-based systems have shown considerable promise in protecting insulin from gastrointestinal degradation, enhancing intestinal absorption, and enabling controlled drug release. These advantages make oral insulin delivery a potentially patient-friendly alternative to conventional injections. However, several challenges still limit clinical translation, including low bioavailability, formulation stability issues, large-scale manufacturing constraints, and regulatory complexities. Safety concerns related to long-term nanoparticle exposure must also be carefully addressed through rigorous evaluation. Standardization of regulatory guidelines and improved characterization techniques are essential for successful commercialization. Integration of advanced technologies such as artificial intelligence and predictive modeling may further optimize formulation design. Collaborative interdisciplinary research involving pharmaceutical scientists, nanotechnologists, clinicians, and regulatory experts is crucial. Continued innovation in materials science and manufacturing processes will support scalable production. Ultimately, QbD-guided nanoparticle systems hold strong potential to revolutionize oral insulin therapy. Successful translation could significantly improve diabetes management and patient quality of life.

References

1. Aguirre, T. A., Teijeiro-Osorio, D., Rosa, M., Coulter, I. S., Alonso, M. J., & Brayden, D. J. (2016). Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Advanced Drug Delivery Reviews, 106, 223–241.
2. Fonte, P., Araújo, F., Reis, S., & Sarmento, B. (2013). Oral insulin delivery: How far are we? Journal of Diabetes Science and Technology, 7(2), 520–531.
3. He, C., Yin, L., Tang, C., & Yin, C. (2012). Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery. Biomaterials, 33(33), 8569–8578.
4. Homayun, B., Lin, X., & Choi, H. J. (2019). Challenges and recent progress in oral drug delivery systems for biologics. Advanced Drug Delivery Reviews, 151–152, 3–20.
5. Hua, S., Marks, E., Schneider, J. J., & Keely, S. (2015). Advances in oral nanodelivery systems for colon targeted drug delivery. Frontiers in Pharmacology, 6, 138.

© 2026 EIJO, All Rights Reserved

6. Iyer, H., Khedkar, A., & Verma, M. (2010). Oral insulin—A review of current status. Diabetes, Obesity and Metabolism, 12(3), 179–185.
7. Jain, K. K. (2020). An overview of drug delivery systems. Methods in Molecular Biology, 2059, 1–54.
8. Jampilek, J., & Kralova, K. (2021). Nanotechnology for drug delivery: Current trends and future perspectives. Nanomaterials, 11(6), 1562.
9. Lee, S. H., Moroz, E., Castagner, B., & Leroux, J. C. (2014). Activatable cell penetrating peptide–peptide conjugates for targeted insulin delivery. Journal of Controlled Release, 193, 128–136.
10. Li, Y., Yang, H. Y., Lee, D. S., & Kim, D. H. (2022). Advances in oral insulin delivery using nanotechnology. Pharmaceutics, 14(3), 486.
11. Mahato, R. I., Narang, A. S., Thoma, L., & Miller, D. D. (2003). Emerging trends in oral delivery of peptide and protein drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 20(2-3), 153–214.
12. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., … Shin, H. S. (2018). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16, 71.
13. Pridgen, E. M., Alexis, F., & Farokhzad, O. C. (2015). Polymeric nanoparticle drug delivery technologies. Molecular Pharmaceutics, 12(6), 1986–1996.
14. Rahmani, S., Azarpira, N., & Mokhtari, M. (2024). Recent advances in nanoparticle-mediated oral insulin delivery. International Journal of Pharmaceutics, 650, 123781.
15. Sarmento, B., Ferreira, D., Veiga, F., & Ribeiro, A. (2007). Characterization of insulin-loaded alginate nanoparticles. International Journal of Pharmaceutics, 311(1–2), 1–10.
16. Sonaje, K., Lin, Y. H., Juang, J. H., Wey, S. P., Chen, C. T., Sung, H. W. (2009). Self-assembled nanoparticles for oral insulin delivery. Biomaterials, 30(12), 2329–2339.
17. Torchilin, V. P. (2014). Multifunctional nanocarriers. Nature Reviews Drug Discovery, 13(11), 813–827.
18. Varshosaz, J., & Taymouri, S. (2023). Nanocarriers for oral insulin delivery: Challenges and opportunities. Drug Delivery and Translational Research, 13, 1850–1865.
19. Verma, A., & Stellacci, F. (2010). Effect of surface properties on nanoparticle–cell interactions. Small, 6(1), 12–21.
20. Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., … Gu, Z. (2015). Microneedle array patches for glucose-responsive insulin delivery. Proceedings of the National Academy of Sciences, 112(27), 8260–8265.
21. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: Therapeutic applications. Clinical Pharmacology & Therapeutics, 83(5), 761–769.
22. Zhang, Y., Chan, H. F., & Leong, K. W. (2013). Advanced materials and processing for drug delivery. Advanced Drug Delivery Reviews, 65(1), 104–120.
23. Zhao, Y., Yang, X., & Zhang, Y. (2024). Quality-by-Design approaches in nanoparticle drug delivery systems. Pharmaceutics, 16(2), 247.

© 2026 EIJO, All Rights Reserved